Dr. Pollock’s work includes clinical studies examining neurochemical selectivity, pharmacokinetics, and neurophysiological-therapeutic effects of conventional or newly derived/modified agents for the treatment of depression and the behavioral disturbances of dementia, and examination of age-related changes in drug metabolism and pharmacodynamics toward optimizing treatment with antidepressants and antipsychotics. He has had a leadership role in numerous clinical trials and the U.S. National Institutes of Health has continuously funded his research since 1990.
Bruce G. Pollock, M.D., Ph.D., FRCP(C), FCP is the Vice President, Research and Director, Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health (CAMH), Professor of Psychiatry & Pharmacology and Director, Division of Geriatric Psychiatry at the University of Toronto.
Dr. Pollock earned his M.D. from the Faculty of Medicine of the University of Toronto, and his Ph.D. in pharmacology from the University of Pittsburgh School of Medicine. Dr. Pollock has authored more than 300 published articles and is listed by ISI as among the 1% most cited authors in the field of geriatric psychiatry.
Dr. Pollock is a Distinguished Fellow of the American Psychiatric Association (APA), a Fellow of the Canadian Psychiatric Association, and has been honored with the Distinguished Investigator Award of the American Association for Geriatric Psychiatry. He has also been awarded the Jack Weinberg Memorial Award for excellence in Geriatric Psychiatry from the APA, the Award for Research in Geriatric Psychiatry by the American College of Psychiatrists, and was recipient of the William B. Abrams Award in Geriatric Clinical Pharmacology from the American Society for Clinical Pharmacology and Therapeutics (ASCPT) in 2014.